Drug intelligence / Profile preview

XL-001

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal

Overview

XL-001 is a novel compound identified through in silico screening and medicinal chemistry modifications. It functions as a highly affine and selective inverse agonist of the cannabinoid receptor type 2 (CB2). This drug has been shown to inhibit CB2-triggered activation of β-catenin and fibrotic injury, and to ameliorate kidney injury, fibrosis, and inflammation in preclinical models of kidney disease, including unilateral ureteral obstruction and ischemia/reperfusion injury. Its development aims to provide a strategy against fibrotic kidney diseases.

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on XL-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XL-001.

Explore the full profile